JP2009508476A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009508476A5 JP2009508476A5 JP2008529350A JP2008529350A JP2009508476A5 JP 2009508476 A5 JP2009508476 A5 JP 2009508476A5 JP 2008529350 A JP2008529350 A JP 2008529350A JP 2008529350 A JP2008529350 A JP 2008529350A JP 2009508476 A5 JP2009508476 A5 JP 2009508476A5
- Authority
- JP
- Japan
- Prior art keywords
- cell line
- antibody
- polypeptide
- produced
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cell Anatomy 0.000 claims 23
- 108090000765 processed proteins & peptides Proteins 0.000 claims 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 229920001184 polypeptide Polymers 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- 108091033319 polynucleotide Proteins 0.000 claims 5
- 102000040430 polynucleotide Human genes 0.000 claims 5
- 239000002157 polynucleotide Substances 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 238000000034 method Methods 0.000 claims 3
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims 2
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 claims 2
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims 2
- 150000002482 oligosaccharides Polymers 0.000 claims 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 101000635804 Homo sapiens Tissue factor Proteins 0.000 claims 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims 1
- 102000004856 Lectins Human genes 0.000 claims 1
- 108090001090 Lectins Proteins 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 235000021120 animal protein Nutrition 0.000 claims 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 1
- 229960000074 biopharmaceutical Drugs 0.000 claims 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 102000057041 human TNF Human genes 0.000 claims 1
- 210000004408 hybridoma Anatomy 0.000 claims 1
- 239000002523 lectin Substances 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000001613 neoplastic effect Effects 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 238000001890 transfection Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US71305505P | 2005-08-31 | 2005-08-31 | |
| US71285805P | 2005-08-31 | 2005-08-31 | |
| PCT/US2006/034382 WO2007028106A2 (en) | 2005-08-31 | 2006-08-31 | Host cell lines for production of antibody constant region with enhanced effector function |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009508476A JP2009508476A (ja) | 2009-03-05 |
| JP2009508476A5 true JP2009508476A5 (enExample) | 2009-09-24 |
Family
ID=37809622
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008529350A Pending JP2009508476A (ja) | 2005-08-31 | 2006-08-31 | 高められたエフェクター機能をもつ抗体定常領域の製造用の宿主細胞株 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20090214528A1 (enExample) |
| EP (1) | EP1937313A4 (enExample) |
| JP (1) | JP2009508476A (enExample) |
| KR (1) | KR20080048505A (enExample) |
| AU (1) | AU2006287224A1 (enExample) |
| BR (1) | BRPI0616600A2 (enExample) |
| CA (1) | CA2621236A1 (enExample) |
| MX (1) | MX2008003054A (enExample) |
| WO (1) | WO2007028106A2 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2369292C (en) | 1999-04-09 | 2010-09-21 | Kyowa Hakko Kogyo Co. Ltd. | Method of modulating the activity of functional immune molecules |
| FR2807767B1 (fr) * | 2000-04-12 | 2005-01-14 | Lab Francais Du Fractionnement | Anticorps monoclonaux anti-d |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| CA2763768A1 (en) * | 2009-05-29 | 2010-12-02 | Glaxosmithkline Llc | Methods of administration of thrombopoietin agonist compounds |
| SG10201407983VA (en) * | 2009-12-18 | 2015-01-29 | Csl Ltd | Method of purifying polypeptides |
| GB201003701D0 (en) * | 2010-03-05 | 2010-04-21 | Cilian Ag | System for the expression of a protein |
| WO2013087911A1 (en) | 2011-12-16 | 2013-06-20 | Synthon Biopharmaceuticals B.V. | Compounds and methods for treating inflammatory diseases |
| HUE035887T2 (en) | 2012-12-05 | 2018-05-28 | Alnylam Pharmaceuticals Inc | PCSK9 iRNA preparations and methods for their use |
| US9677105B2 (en) | 2013-03-14 | 2017-06-13 | Momenta Pharmaceuticals, Inc. | Methods of cell culture |
| US8956830B2 (en) | 2013-03-14 | 2015-02-17 | Momenta Pharmaceuticals, Inc. | Methods of cell culture |
| US9217168B2 (en) | 2013-03-14 | 2015-12-22 | Momenta Pharmaceuticals, Inc. | Methods of cell culture |
| AU2015267052A1 (en) * | 2014-05-27 | 2016-12-15 | Academia Sinica | Compositions and methods relating to universal glycoforms for enhanced antibody efficacy |
| CN108348541A (zh) * | 2015-08-25 | 2018-07-31 | 阿尔尼拉姆医药品有限公司 | 用于治疗前蛋白转化酶枯草杆菌蛋白酶kexin(pcsk9)基因相关障碍的方法和组合物 |
| US10465003B2 (en) * | 2016-02-05 | 2019-11-05 | Janssen Biotech, Inc. | Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes |
| IL268007B2 (en) * | 2017-01-30 | 2025-05-01 | Janssen Biotech Inc | Anti-tnf antibodies, compositions, and methods for the treatment of active psoriatic arthritis |
| AU2017398101B2 (en) * | 2017-02-07 | 2025-02-06 | Janssen Biotech, Inc. | Anti-TNF antibodies, compositions, and methods for the treatment of active Ankylosing Spondylitis |
| KR102323342B1 (ko) * | 2019-04-26 | 2021-11-08 | 주식회사 와이바이오로직스 | IL-17A 및 TNF-α에 특이적으로 결합하는 이중표적 항체 |
| JP2021518854A (ja) * | 2019-05-08 | 2021-08-05 | ノバルティス アーゲー | Ｔ１ｄｍ及び膵島炎の治療に使用するための抗ｃｄ４０抗体 |
| CA3138241A1 (en) | 2019-05-23 | 2020-11-26 | Janssen Biotech, Inc. | Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha |
| EP4596046A3 (en) | 2020-05-21 | 2025-10-22 | Janssen Biotech, Inc. | Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1079704A (en) | 1912-06-19 | 1913-11-25 | Dallas C Hathaway | Combination tire valve-stem and pressure-gage. |
| DE3167442D1 (en) * | 1980-07-07 | 1985-01-10 | Nat Res Dev | Improvements in or relating to cell lines |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4816597A (en) * | 1983-10-02 | 1989-03-28 | New Jersey Institute Of Technology | Dental restorative materials based upon blocked isocyanates |
| GB8421551D0 (en) | 1984-08-24 | 1984-09-26 | Ici Plc | Water-soluble dye |
| DE69632465T2 (de) | 1995-06-07 | 2005-06-23 | Ortho-Mcneil Pharmaceutical, Inc. | Cdr-transplantierte antikörper gegen "tissue factor" und verfahren zur deren verwendung |
| DE69823046T2 (de) * | 1997-01-16 | 2005-03-31 | Neose Technologies, Inc. | Praktische in vitro sialylierung von rekombinanten glykpproteinen |
| JP4334141B2 (ja) * | 1998-04-20 | 2009-09-30 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作 |
| CA2369292C (en) * | 1999-04-09 | 2010-09-21 | Kyowa Hakko Kogyo Co. Ltd. | Method of modulating the activity of functional immune molecules |
| UA81743C2 (uk) | 2000-08-07 | 2008-02-11 | Центокор, Инк. | МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ |
| US6946292B2 (en) * | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| CA2438148A1 (en) | 2001-02-15 | 2002-08-29 | Centocor, Inc. | Chemically defined medium for cultured mammalian cells |
| CN1930288B (zh) * | 2002-04-09 | 2012-08-08 | 协和发酵麒麟株式会社 | 基因组被修饰的细胞 |
| JPWO2003085118A1 (ja) * | 2002-04-09 | 2005-08-11 | 協和醗酵工業株式会社 | 抗体組成物の製造方法 |
| WO2003084570A1 (en) * | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | DRUG CONTAINING ANTIBODY COMPOSITION APPROPRIATE FOR PATIENT SUFFERING FROM FcϜRIIIa POLYMORPHISM |
| JP2006526641A (ja) | 2003-05-30 | 2006-11-24 | セントカー・インコーポレーテツド | 抗−組織因子抗体を用いる腫瘍成長を抑制する方法 |
| US7605235B2 (en) | 2003-05-30 | 2009-10-20 | Centocor, Inc. | Anti-tissue factor antibodies and compositions |
-
2006
- 2006-08-31 KR KR1020087007406A patent/KR20080048505A/ko not_active Ceased
- 2006-08-31 MX MX2008003054A patent/MX2008003054A/es not_active Application Discontinuation
- 2006-08-31 CA CA002621236A patent/CA2621236A1/en not_active Abandoned
- 2006-08-31 JP JP2008529350A patent/JP2009508476A/ja active Pending
- 2006-08-31 EP EP06814116A patent/EP1937313A4/en not_active Withdrawn
- 2006-08-31 WO PCT/US2006/034382 patent/WO2007028106A2/en not_active Ceased
- 2006-08-31 AU AU2006287224A patent/AU2006287224A1/en not_active Abandoned
- 2006-08-31 BR BRPI0616600-8A patent/BRPI0616600A2/pt not_active Application Discontinuation
- 2006-08-31 US US12/065,178 patent/US20090214528A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009508476A5 (enExample) | ||
| US20240392002A1 (en) | Anti-ror antibody constructs | |
| CN107217042B (zh) | 一种生产无岩藻糖基化蛋白的基因工程细胞系及其建立方法 | |
| CN113038964B (zh) | 超长效胰岛素-fc融合蛋白及使用方法 | |
| TWI586686B (zh) | 胰高血糖素受體之人類抗體 | |
| US12018073B2 (en) | Antagonists targeting the TGF-β pathway | |
| CA2984350A1 (en) | Single-chain cd40-receptor agonist proteins | |
| CA3002602C (en) | Single-chain cd27-receptor agonist proteins | |
| US20200384061A1 (en) | Fusion Protein Including BDNF | |
| CN106519025A (zh) | 利用cdr的氨基酸取代来改变抗体等电点的方法 | |
| JP2008537874A5 (enExample) | ||
| TW200415241A (en) | Fc fusion proteins of human erythropoietin with high biological activities | |
| CA2663042A1 (en) | Serum albumin binding proteins with long half-lives | |
| CN111601821B (zh) | 具有对FcRn的亲和力提高以及对至少一个Fc片段受体的亲和力提高的Fc片段的变体 | |
| JPH01502669A (ja) | 精製された血小板由来の成長因子及びその精製方法 | |
| JP2014530001A5 (enExample) | ||
| AU2019327493A1 (en) | Combination therapies comprising sirp alpha-based chimeric proteins | |
| WO2015172305A1 (zh) | 抑制taci-baff复合物形成的融合蛋白及其制法和用途 | |
| JP2018533948A (ja) | 一本鎖ｌｉｇｈｔ受容体アゴニストタンパク質 | |
| EP3830129A2 (en) | Multispecific treg binding molecules | |
| JP2010512306A5 (enExample) | ||
| JP2009524428A5 (enExample) | ||
| CN119907811A (zh) | 针对cd28的多功能分子 | |
| CA3003511A1 (en) | Single-chain tl1a receptor agonist proteins | |
| WO2019196603A1 (zh) | Gcgr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用 |